Beacon Therapeutics Secures $170M in Series B Funding to Accelerate Progress in Ophthalmic Gene Therapy Development

London and Cambridge, MA, July 3, 2024 (PRNewswire) -- Beacon Therapeutics has raised $170 million in Series B funding to advance its ophthalmic gene therapy initiatives, supported by Forbion and other investors. The funding will expedite development of AGTC-501 and other pipeline projects, while new appointments strengthen the company's board governance.

Read full article here.